Mesoblast (NASDAQ:MESO) Upgraded by Cantor Fitzgerald to "Strong-Buy" Rating

Mesoblast (NASDAQ:MESO - Get Free Report) was upgraded by equities research analysts at Cantor Fitzgerald to a "strong-buy" rating in a research note issued to investors on Monday, March 31st,Zacks.com reports. Cantor Fitzgerald also issued estimates for Mesoblast's FY2025 earnings at ($0.71) EPS.

Other analysts have also issued reports about the stock. Piper Sandler reiterated an "overweight" rating and set a $24.00 target price (up from $15.00) on shares of Mesoblast in a report on Friday, February 7th. Jefferies Financial Group lowered Mesoblast from a "buy" rating to a "hold" rating in a research report on Monday, December 23rd. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Mesoblast presently has a consensus rating of "Moderate Buy" and a consensus target price of $18.00.

Mesoblast Stock Down 0.3 %

NASDAQ:MESO traded down $0.04 during midday trading on Monday, reaching $10.37. 132,821 shares of the stock traded hands, compared to its average volume of 290,105. Mesoblast has a 12 month low of $4.60 and a 12 month high of $22.00. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. The company has a fifty day moving average of $15.54 and a 200 day moving average of $13.43.

Remove Ads

Institutional Investors Weigh In On Mesoblast

Hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its position in shares of Mesoblast by 1,503.3% during the 4th quarter. Bank of America Corp DE now owns 290,728 shares of the company's stock valued at $5,756,000 after acquiring an additional 272,595 shares during the period. Oaktree Capital Management LP purchased a new stake in Mesoblast in the fourth quarter worth about $3,556,000. Strategic Financial Concepts LLC bought a new position in shares of Mesoblast in the fourth quarter worth about $2,744,000. Prosperity Wealth Management Inc. lifted its position in shares of Mesoblast by 2.0% during the 4th quarter. Prosperity Wealth Management Inc. now owns 93,245 shares of the company's stock valued at $1,846,000 after buying an additional 1,795 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of Mesoblast by 1,174.2% during the 1st quarter. GAMMA Investing LLC now owns 85,513 shares of the company's stock valued at $1,067,000 after acquiring an additional 78,802 shares during the period. 1.43% of the stock is currently owned by hedge funds and other institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.